Cargando…

Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study

OBJECTIVES: Both prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are increasingly prevalent conditions, which frequently coexist in men. Here, we set out to specifically examine the impact of a PCa diagnosis and its treatment on T2DM treatment. SETTING: This study uses observational data f...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawley, Danielle, Garmo, Hans, Rudman, Sarah, Stattin, Pär, Zethelius, Björn, Armes, Jo, Holmberg, Lars, Adolfsson, Jan, Van Hemelrijck, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857670/
https://www.ncbi.nlm.nih.gov/pubmed/29549214
http://dx.doi.org/10.1136/bmjopen-2017-020787
_version_ 1783307511300882432
author Crawley, Danielle
Garmo, Hans
Rudman, Sarah
Stattin, Pär
Zethelius, Björn
Armes, Jo
Holmberg, Lars
Adolfsson, Jan
Van Hemelrijck, Mieke
author_facet Crawley, Danielle
Garmo, Hans
Rudman, Sarah
Stattin, Pär
Zethelius, Björn
Armes, Jo
Holmberg, Lars
Adolfsson, Jan
Van Hemelrijck, Mieke
author_sort Crawley, Danielle
collection PubMed
description OBJECTIVES: Both prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are increasingly prevalent conditions, which frequently coexist in men. Here, we set out to specifically examine the impact of a PCa diagnosis and its treatment on T2DM treatment. SETTING: This study uses observational data from Prostate Cancer database Sweden Traject. PARTICIPANTS: The study was undertaken in a cohort of 16 778 men with T2DM, of whom 962 were diagnosed with PCa during mean follow-up of 2.5 years. PRIMARY AND SECONDARY OUTCOME MEASURES: We investigated the association between PCa diagnosis and escalation in T2DM treatment in this cohort. A treatment escalation was defined as a new or change in anti-T2DM prescription, as recorded in the prescribed drug register (ie, change from diet to metformin or sulphonylurea or insulin). We also investigated how PCa diagnosis was associated with two treatment escalations. Multivariate Cox proportional hazards regression with age as a time scale was used while adjusting for educational level and initial T2DM treatment. RESULTS: We found no association between PCa diagnosis and risk of a single treatment escalation (HR 0.99, 95% CI 0.87 to 1.13). However, PCa diagnosis was associated with an increased risk of receiving two consecutive T2DM treatment escalations (HR 1.75, 95% CI 1.38 to 2.22). This increase was strongest for men on gonadotropin-releasing hormone (GnRH) agonists (HR 3.08, 95% CI 2.14 to 4.40). The corresponding HR for men with PCa not on hormonal treatment was 1.40 (95% CI 1.03 to 1.92) and for men with PCa on antiandrogens 0.91 (95% CI 0.29 to 2.82). CONCLUSIONS: Men with T2DM who are diagnosed with PCa, particularly those treated with GnRH agonists, were more likely to have two consecutive escalations in T2DM treatment. This suggests a need for closer monitoring of men with both PCa and T2DM, as coexistence of PCa and its subsequent treatments could potentially worsen T2DM control.
format Online
Article
Text
id pubmed-5857670
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58576702018-03-20 Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study Crawley, Danielle Garmo, Hans Rudman, Sarah Stattin, Pär Zethelius, Björn Armes, Jo Holmberg, Lars Adolfsson, Jan Van Hemelrijck, Mieke BMJ Open Oncology OBJECTIVES: Both prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are increasingly prevalent conditions, which frequently coexist in men. Here, we set out to specifically examine the impact of a PCa diagnosis and its treatment on T2DM treatment. SETTING: This study uses observational data from Prostate Cancer database Sweden Traject. PARTICIPANTS: The study was undertaken in a cohort of 16 778 men with T2DM, of whom 962 were diagnosed with PCa during mean follow-up of 2.5 years. PRIMARY AND SECONDARY OUTCOME MEASURES: We investigated the association between PCa diagnosis and escalation in T2DM treatment in this cohort. A treatment escalation was defined as a new or change in anti-T2DM prescription, as recorded in the prescribed drug register (ie, change from diet to metformin or sulphonylurea or insulin). We also investigated how PCa diagnosis was associated with two treatment escalations. Multivariate Cox proportional hazards regression with age as a time scale was used while adjusting for educational level and initial T2DM treatment. RESULTS: We found no association between PCa diagnosis and risk of a single treatment escalation (HR 0.99, 95% CI 0.87 to 1.13). However, PCa diagnosis was associated with an increased risk of receiving two consecutive T2DM treatment escalations (HR 1.75, 95% CI 1.38 to 2.22). This increase was strongest for men on gonadotropin-releasing hormone (GnRH) agonists (HR 3.08, 95% CI 2.14 to 4.40). The corresponding HR for men with PCa not on hormonal treatment was 1.40 (95% CI 1.03 to 1.92) and for men with PCa on antiandrogens 0.91 (95% CI 0.29 to 2.82). CONCLUSIONS: Men with T2DM who are diagnosed with PCa, particularly those treated with GnRH agonists, were more likely to have two consecutive escalations in T2DM treatment. This suggests a need for closer monitoring of men with both PCa and T2DM, as coexistence of PCa and its subsequent treatments could potentially worsen T2DM control. BMJ Publishing Group 2018-03-16 /pmc/articles/PMC5857670/ /pubmed/29549214 http://dx.doi.org/10.1136/bmjopen-2017-020787 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Oncology
Crawley, Danielle
Garmo, Hans
Rudman, Sarah
Stattin, Pär
Zethelius, Björn
Armes, Jo
Holmberg, Lars
Adolfsson, Jan
Van Hemelrijck, Mieke
Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
title Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
title_full Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
title_fullStr Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
title_full_unstemmed Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
title_short Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
title_sort does a prostate cancer diagnosis affect management of pre-existing diabetes? results from pcbase sweden: a nationwide cohort study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857670/
https://www.ncbi.nlm.nih.gov/pubmed/29549214
http://dx.doi.org/10.1136/bmjopen-2017-020787
work_keys_str_mv AT crawleydanielle doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT garmohans doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT rudmansarah doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT stattinpar doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT zetheliusbjorn doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT armesjo doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT holmberglars doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT adolfssonjan doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy
AT vanhemelrijckmieke doesaprostatecancerdiagnosisaffectmanagementofpreexistingdiabetesresultsfrompcbaseswedenanationwidecohortstudy